Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

NCT05812157 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Axial Spondyloarthritis

Interventions

DIETARY_SUPPLEMENT: Daily dietary supplementation with Fibruline
DRUG: Anti-IL-17 therapy

Sponsor

Centre Hospitalier Universitaire de Nīmes